 |
 |
Dear Me: If you want to correspond in private about my experience in the study, email me at [log in to unmask] Bob ----- Original Message ----- From: "Me" <[log in to unmask]> To: <[log in to unmask]> Sent: Saturday, April 12, 2003 11:04 AM Subject: New Research Study for Parkinson's > Hi all, > > I just read an ad in our local newspaper advertising a new research study > being run at Duke University, testing a new drug for Parkinson's. The > website for this research study is: www.pdstudy.com. > > Below is a description of the study and the drug they are testing. It is a > national study, and is being conducted at many sites around the country. > > Have any of you heard of this study, or this drug? I'm considering > volunteering for it, but I don't want to do anything that will exacerbate my > PD symptoms. Just wondering if anyone is familiar with this study. Any > input would be appreciated. > > > > PRECEPT STUDY: > Physician Information > > The following information on this study for physicians can be printed out > and given to your primary care doctor or neurologist. > > Clinical Research Study Inclusion-Exclusion Criteria for Physicians > > The PRECEPT Study is a randomized, double-blind, placebo-controlled, > dose-finding study to assess the efficacy and safety of CEP-1347 in patients > with early Parkinson's disease. > > CEP-1347 is a potent inhibitor of members of the mixed lineage kinase (MLK) > family. MLK family members are key participants in the activation of c-Jun > N-terminal kinase (JNK), which is thought to underlie neuronal dysfunction > and subsequent death. Research at Cephalon and H. Lundbeck A/S has shown > that CEP-1347 enhances the survival of neurons that produce dopamine. > Additionally, animal models of Parkinson's disease have shown that CEP-1347 > protects the dopamine-producing neurons in the specific area of the brain > affected by Parkinson's disease. > > The primary objective is to determine if treatment with CEP-1347 delays the > time to onset of disability sufficient to require dopaminergic therapy. > > ---------------------------------------------------------------------- > To sign-off Parkinsn send a message to: mailto:[log in to unmask] > In the body of the message put: signoff parkinsn > ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn